AllSci News
Sino Bio expands GSK partnership into respiratory, securing China rights to USD 4.5b inhaler franchise
GSK is extending its Sino Bio GSK collaboration into respiratory medicine, handing China commercialization rights for two of its highest-revenue inhaled...
AstraZeneca secures ex-China rights to Sino Bio's TQC3721 in USD 2.1b respiratory deal
AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2.1...
Xiaflex wins first-ever FDA approval pathway for plantar fibromatosis with Phase III success
Keenova Therapeutics has reported that collagenase clostridium histolyticum (Xiaflex) met its primary endpoint in a pivotal Phase III trial for plantar...
Bayer aims to accelerate clinical trials through first academic medical center alliance in Colorado
Bayer announced a clinical trial collaboration alliance with the University of Colorado Anschutz Medical Campus, UCHealth, and Children’s Hospital Colorado, marking the…
FDA bestows BTD on Merck KGaA’s enpatoran for lupus skin manifestations
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, announced that the US FDA has granted…
Evogene pairs ChemPass AI with Tel Aviv University to accelerate academic drug discovery pipeline
Israel-based computational chemistry company Evogene Ltd. (Nasdaq: EVGN) and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have announced…
Chicago Uni engineers bacteria to deliver immunotherapy directly to pancreatic tumors
The University of Chicago has received a USD 1.75 million National Cancer Institute R01 award to develop genetically engineered Bifidobacterium as a...
Helix secures AstraZeneca partnership to power drug discovery with US genomic data
AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and...
Boehringer Ingelheim acquires viral vector platform from Prime Vector Technologies for cancer vaccines
Boehringer Ingelheim has entered a license agreement with Germany-based Prime Vector Technologies GmbH (PVT) to acquire exclusive rights to its Orf virus...
Merck ends Phase II Alzheimer's trial of MK-1167 after interim efficacy failure
Merck's Phase II MK-1167-008 trial evaluating MK-1167, an oral M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 PAM), in mild to...
Compass Pathways' COMP360 becomes first classic psychedelic to prove durable six-month benefit in TRD
Compass Pathways plc (Nasdaq: CMPS) has reported 26-week data from its second Phase III trial of COMP360, a synthetic psilocybin formulation for...
Kailera's oral GLP-1 agonist HRS-7535 delivers weight loss but trails injectable rivals in obesity race
Kailera Therapeutics (Nasdaq: KLRA) reported positive topline data from two Hengrui Pharma-sponsored Phase III trials of HRS-7535, an oral small molecule...
Semnur secures USD 100m from Kazakhstan investor to advance non-opioid pain candidate
Palo Alto-based Semnur Pharmaceuticals, Inc. (OTC: SMNR), a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), announced the signing of a...
EMA begins phased review of Revolution's daraxonrasib as FDA filing nears completion
Revolution Medicines (Nasdaq: RVMD) has initiated a rolling submission of a New Drug Application (NDA) to the US FDA for daraxonrasib (RMC-6236), an...
Insilico's AI-designed TNIK inhibitor rentosertib advances to Phase III IPF trial
Insilico Medicine (HKEX: 3696) has initiated a Phase III clinical trial for rentosertib (formerly ISM001-055 / INS018055), its first-in-class oral TNIK...
The AllSci Brief
Free, systematic R&D and deal news. Daily.